Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03939026
Title Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma (ALPHA)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Allogene Therapeutics
Indications

diffuse large B-cell lymphoma

follicular lymphoma

Therapies

UCART19

ALLO-647 + Cyclophosphamide + Fludarabine

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.